Joining us now to discuss the impact to pharma stocks is Evan Seagerman, Beimo, senior biioarma analyst. Evan, great to have you with us. Um, first I wanted to get your thoughts on the deal that was just announced within the past half hour.Breaking news. Breaking news for sure. Merc shares are higher.Uh, and we knew that it faced the patent cliff for Katruda in 2028. Right. So, one of the things I've always been saying with Merc and kind of the reason of my downgrade back in December was they had this huge ...